BIOCRYST PHARMACEUTICALS INC (BCRX) research
BIOCRYST PHARMACEUTICALS INC- Sector
- Biotechnology
- Last price
- $8.78
- As of
BIOCRYST PHARMACEUTICALS INC (BCRX): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
As of . Source: SEC EDGAR filings for BCRX. Method and limitations.
Share the BCRX intelligence card
See BCRX live in the terminal
Track BCRX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live BCRX terminal, freeActive signals for BCRX
- highCONSENSUS_BUY
4 tracked funds increased BCRX this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 79% of BCRX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +1708% to BCRX (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +226% to BCRX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +76% to BCRX (2026Q2)
FREE, NO ACCOUNT
Every signal on BCRX, as it fires
You are seeing 5 of 27 signals recorded on BCRX since 2026-06-21.
The five above landed across 2 days. The other 22 were recorded on 3 other days. 21 of the 27 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BCRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 09058V103 · 2026Q2 | $67.8M | 0.05% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 09058V103 · 2026Q2 | $33.9M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 09058V103 · 2026Q2 | $25.3M | 0.03% | , |
| CITADEL ADVISORS LLCCUSIP 09058V103 · 2026Q2 | $17.6M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 09058V103 · 2026Q2 | $4.9M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP 09058V103 · 2026Q2 | $4.1M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 09058V103 · 2026Q2 | $2.6M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BCRX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BCRX against its peers
BCRX's operating margin of 39.0% ranks in the 96th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | BCRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 875M USD | 84.0M USD | 89 | 13 |
| Operating margin | 39.0% | -307.4% | 96 | 12 |
| Net margin | 30.2% | -314.9% | 89 | 13 |
| Return on equity | n/a | -32.2% | n/a | 20 |
| P / E | 7.2x | n/a | n/a | 3 |
Peers (22): AUPH, SRPT, PVLA, SLS, ZBIO, URGN, VCEL, KOD, BEAM, CMPS, VERA, RAPP, ADMA, VRDN, AGIO, MESO, VIR, MLYS, GHRS, IRON, NRIX, NAMS. Left out: BRVE (no annual filing), GENB (no annual filing), COAG (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (BCRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more BCRX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BCRXand get the insider, 13F, options, and confluence read in one view.